Pembroria

Biocad is a leading Russian biotechnology company specializing in the research, development, and large-scale manufacturing of innovative biologics and biosimilars. The company is the developer of Pembroria, a biosimilar of the PD-1 inhibitor pembrolizumab (Keytruda), which has received regulatory approval in Russia and Vietnam for various oncology indications. Biocad's diverse portfolio includes original monoclonal antibodies such as prolgolimab (anti-PD-1) and netakimab (anti-IL-17), as well as biosimilars for blockbuster drugs like bevacizumab and trastuzumab. With a vertically integrated business model, Biocad controls the entire value chain from molecular discovery to clinical trials and GMP-certified production. The company is a key player in the Russian pharmaceutical market and is actively expanding its presence in international markets, particularly in Southeast Asia, Latin America, and the MENA region.